Latest Market Access News

Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

Spenda Limited's SPXOB securities have been suspended from trading by the ASX due to non-compliance with listing requirements. The suspension affects only this security class, leaving other Spenda securities unaffected.

International Graphite Limited has appointed Liam Farley, CEO of Xcelsior Capital, to its board and increased its placement to $4.4 million, reinforcing its strategic push in graphite processing across Australia and Europe.

Saluda Medical has obtained FDA approval for its CAP24 surgical paddle lead, a first-of-its-kind device designed for closed-loop spinal cord stimulation, poised to broaden its US market reach and engage new surgical specialties.

SRJ Technologies' subsidiary ACE inks a strategic MOU with Australian robotics leader Nexxis, aiming to combine cutting-edge robotic platforms with advanced data analytics to enhance asset inspections in the energy sector.

Pacific Edge reported a $35.8 million loss in FY26 amid a 47% revenue drop following Medicare coverage loss, but a draft Medicare policy and $36.1 million capital raise set the stage for recovery.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

Pure Resources and Rice University have secured 'Awardable' status on the DARPA ERIS Marketplace for their advanced Carbon Nanotube Fibre 3D thermal management technology, positioning them for potential US Department of Defense contracts.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

Centuria Capital Group has successfully secured $265 million through institutional placement and entitlement offers, setting the stage for a $35 million retail entitlement offer to follow.

CleanSpace's AGILE respirator has achieved AS/NZS 17420.2:2021 certification, paving the way for commercialisation in Australia and New Zealand alongside its recent European approval.